Literature DB >> 33044172

Application of percutaneous transluminal sharp recanalization in transjugular intrahepatic portosystemic shunt for patients with chronic portal vein occlusion.

Mingan Li1, Junyang Luo1, Junwei Chen1, Chun Wu1, Tao Pan1, Mingsheng Huang1, Zaibo Jiang1.   

Abstract

PURPOSE: We aimed to evaluate the feasibility and safety of a modified technique for portal vein recanalization, percutaneous transluminal sharp recanalization (PTSR), when performing transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of chronic portal vein occlusion (CPVO) and portal hypertension.
METHODS: Nine consecutive patients with CPVO and portal hypertension had undergone TIPS and PTSR procedure after failing in conventional percutaneous catheterization from March 2017 to July 2019. Technical success rates, effectiveness, and complications were evaluated. Follow-up of patients' clinical outcomes and shunt patency were performed periodically. Primary and secondary shunt patency were analyzed by Kaplan-Meier method.
RESULTS: The occluded portal veins were successfully recanalized after failing in conventional percutaneous catheterization, and TIPS procedures were completed in all 9 patients. Two patients suffered from procedure-related complications. A portosystemic pressure gradient <12 mmHg, or a percent reduction of 25% to 50% of baseline, was achieved in all 9 patients after TIPS. During the median follow-up period of 28 months (range, 9-36 months), 1 patient experienced recurrent ascites and the other 8 patients remained asymptomatic. The cumulative rates of primary and secondary shunt patency were 66.67% and 100%, respectively, at 2 years.
CONCLUSION: As a supplementary method, PTSR is a feasible and safe method for portal vein recanalization when performing TIPS for patients with CPVO and portal hypertension.

Entities:  

Year:  2021        PMID: 33044172      PMCID: PMC7963390          DOI: 10.5152/dir.2020.20461

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  21 in total

1.  EASL Clinical Practice Guidelines: Vascular diseases of the liver.

Authors: 
Journal:  J Hepatol       Date:  2015-10-26       Impact factor: 25.083

2.  Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Michael Vouche; Robert L Vogelzang; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2015-02-07       Impact factor: 3.464

3.  Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications.

Authors:  Yong Chen; Peng Ye; Yanhao Li; Shuoyi Ma; Jianbo Zhao; Qingle Zeng
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

4.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.

Authors:  Guadalupe Garcia-Tsao; Juan G Abraldes; Annalisa Berzigotti; Jaime Bosch
Journal:  Hepatology       Date:  2016-12-01       Impact factor: 17.425

5.  Transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis and concomitant portal vein thrombosis.

Authors:  Thuong G Van Ha; Justin Hodge; Brian Funaki; Jonathan Lorenz; Jordan Rosenblum; Christopher Straus; Jeff Leef
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Sep-Oct       Impact factor: 2.740

6.  Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.

Authors:  Guohong Han; Xingshun Qi; Chuangye He; Zhanxin Yin; Jianhong Wang; Jielai Xia; Zhiping Yang; Ming Bai; Xiangjie Meng; Jing Niu; Kaichun Wu; Daiming Fan
Journal:  J Hepatol       Date:  2010-08-27       Impact factor: 25.083

7.  Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma.

Authors:  Fabrizio Fanelli; Stefania Angeloni; Filippo Maria Salvatori; Chiara Marzano; Emanuele Boatta; Manuela Merli; Plinio Rossi; Adolfo Francesco Attili; Lorenzo Ridola; Federica Cerini; Oliviero Riggio
Journal:  Dig Liver Dis       Date:  2010-07-15       Impact factor: 4.088

8.  Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation.

Authors:  M Senzolo; J Tibbals; E Cholongitas; C K Triantos; A K Burroughs; D Patch
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

9.  Percutaneous transhepatic intrahepatic portosystemic shunt for variceal bleeding with chronic portal vein occlusion after splenectomy.

Authors:  Junyang Luo; Mingan Li; Youyong Zhang; Haofan Wang; Mingsheng Huang; Zhengran Li; Junwei Chen; Chun Wu; Jiesheng Qian; Shouhai Guan; Zaibo Jiang
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

Review 10.  Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants.

Authors:  Matthew Wu; Michael Schuster; Micheal Tadros
Journal:  J Clin Transl Hepatol       Date:  2019-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.